Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Valeant Pharmaceuticals International Stories

2014-01-08 12:29:08

LONDON, Jan. 8, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Global Dermatophytic Onychomycosis Therapeutics Market 2012-2016 TechNavio's analysts forecast the Global Dermatophytic Onychomycosis Therapeutics market to grow at a CAGR of 7.28 percent over the period 2012-2016. One of the key factors contributing to this market growth is the strong and promising pipeline. The Global Dermatophytic Onychomycosis Therapeutics market has also been...

2013-10-28 08:29:15

DUBLIN, Oct. 28, 2013 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%. Actavis' ANDA product is a generic version of Dow Pharmaceutical Sciences and Valeant Pharmaceuticals International's Acanya(®) Gel, which is indicated for the topical treatment of acne vulgaris in patients 12...

2012-09-05 02:38:52

VANCOUVER, British Columbia, Sept. 5, 2012 /PRNewswire/ -- Pennystocksinsiders.com (PSI) has issued insider trading reports and Equity Research for the following companies: American International Group (NYSE:AIG), Valeant (NYSE:VRX), ARM Holdings (NASDAQ:ARMH), Lowe's (NYSE:LOW), CSX (NYSE:CSX), and Arena (NASDAQ:ARNA). (Logo: http://photos.prnewswire.com/prnh/20120813/HK56225LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full link to...

2012-07-16 10:25:51

MONTREAL, July 16, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Thursday, August 2, 2012 at 8:00 a.m. ET (5:00 a.m. PT) to discuss results for the 2012 second quarter. The dial-in number to participate on this call is (877) 876-8393, confirmation code 10552994. International callers should dial (973) 200-3961, confirmation code...

2012-06-21 02:25:52

MONTREAL, June 21, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) will be hosting an Investor Day today in Florham Park, New Jersey where the Company will be discussing certain business operations, organic growth calculations and other performance metrics, including the Company's quarterly performance trends. In addition, Valeant is reaffirming its financial guidance for 2012 provided in its press release dated May 3, 2012, at the upper end of the...

2012-06-15 02:25:39

MONTREAL, June 15, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that Valeant has agreed to acquire OraPharma, a specialty oral health company that develops and commercializes products that improve and maintain oral health, from Water Street Healthcare Partners, a private equity firm focused exclusively on the health care industry. Total consideration is approximately $312 million and up to $114 million in potential...

2012-06-14 14:21:04

MONTREAL, June 14, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today the successful syndication of $600 million of incremental term loans under its existing senior secured credit facilities to be used to fund repayment of amounts outstanding under its existing $275 million revolving facility and for general corporate purposes, including acquisitions. The incremental term loans will mature in 2019 and have terms that are...

2012-06-07 02:28:48

MONTREAL, June 7, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International (NYSE:VRX) (TSX: VRX) today announced that it will host an Investor Day in Florham Park, New Jersey, on Thursday, June 21, 2012 from 8:30 a.m. to 12:30 p.m. ET. J. Michael Pearson, Valeant's chairman and chief executive officer, and other members of Valeant's management team will discuss the company's strategies and opportunities in each of its business regions. A live video webcast and slide presentation...

2012-05-30 02:25:25

MONTREAL, May 30, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced plans to syndicate $500 million of incremental term loans under its existing senior secured credit facilities to fund repayment of amounts outstanding under its existing $275 million revolving facility and for general corporate purposes, including acquisitions. The incremental term loans will mature in 2019 and are expected to have terms that are similar to the...

2012-05-24 02:27:51

MONTREAL, Quebec, May 24, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that Valeant has agreed to acquire certain assets from Swiss Herbal Remedies Limited, a nutraceutical company that manufactures and markets a broad range of scientifically formulated vitamins, minerals and supplements, for less than one times sales. Total net revenue in 2011 from the acquired assets was approximately C$28 million. The transaction is expected...